Guardion Health Sciences Announces Filing of Certificate of Dissolution
Guardion Health Sciences (NASDAQ: GHSI) has filed a certificate of dissolution with Delaware's Secretary of State on October 30, 2024. The company has closed its stock transfer books and expects to pay stockholders a liquidating dividend totaling approximately $3.25 per share of Common Stock. Following the dissolution, Guardion will only engage in activities necessary to preserve asset value and complete business wind down. The company has received SEC approval to indefinitely suspend its reporting obligations.
Guardion Health Sciences (NASDAQ: GHSI) ha presentato un certificato di scioglimento presso il Segretario di Stato del Delaware il 30 ottobre 2024. L'azienda ha chiuso i suoi libri di trasferimento azionario e prevede di pagare agli azionisti un dividendo liquidatorio che ammonta a circa $3,25 per azione di azioni ordinarie. Dopo lo scioglimento, Guardion si occuperà solo di attività necessarie per preservare il valore degli asset e completare la chiusura dell'attività. L'azienda ha ricevuto l'approvazione della SEC per sospendere indefinitamente i suoi obblighi di reporting.
Guardion Health Sciences (NASDAQ: GHSI) ha presentado un certificado de disolución ante el Secretario de Estado de Delaware el 30 de octubre de 2024. La compañía ha cerrado sus libros de transferencia de acciones y espera pagar a los accionistas un dividendo liquidatorio que totaliza aproximadamente $3.25 por acción de acciones ordinarias. Tras la disolución, Guardion solo se involucrará en actividades necesarias para preservar el valor de los activos y llevar a cabo el cierre del negocio. La compañía ha recibido la aprobación de la SEC para suspender indefinidamente sus obligaciones de reporte.
Guardion Health Sciences (NASDAQ: GHSI)는 2024년 10월 30일 델라웨어 주 국무부에 해산 인증서를 제출했습니다. 회사는 주식 이체 장부를 종료했으며, 주주에게 주당 약 $3.25의 청산 배당금을 지급할 것으로 예상합니다. 해산 이후, Guardion은 자산 가치를 보존하고 사업 종료를 완료하는 데 필요한 활동만 수행할 것입니다. 이 회사는 SEC의 승인을 받아 보고 의무를 무기한 중단할 수 있게 되었습니다.
Guardion Health Sciences (NASDAQ: GHSI) a déposé un certificat de dissolution auprès du Secrétaire d'État du Delaware le 30 octobre 2024. L'entreprise a fermé ses livres de transfert d'actions et prévoit de verser aux actionnaires un dividende liquidatif totalisant environ 3,25 $ par action d'actions ordinaires. Après la dissolution, Guardion ne s'engagera que dans des activités nécessaires à la préservation de la valeur des actifs et à l'achèvement de la liquidation de l'entreprise. L'entreprise a reçu l'approbation de la SEC pour suspendre indéfiniment ses obligations de reporting.
Guardion Health Sciences (NASDAQ: GHSI) hat am 30. Oktober 2024 ein Auflösungszertifikat beim Secretary of State von Delaware eingereicht. Das Unternehmen hat seine Aktienübertragungsbücher geschlossen und erwartet, den Aktionären eine Liquidationsdividende von etwa 3,25 $ pro Aktie des Stammkapitals zu zahlen. Nach der Auflösung wird Guardion sich nur mit Aktivitäten befassen, die notwendig sind, um den Vermögenswert zu erhalten und die Unternehmensabwicklung abzuschließen. Das Unternehmen hat die Genehmigung der SEC erhalten, um seine Berichtspflichten auf unbestimmte Zeit auszusetzen.
- Expected liquidating dividend of approximately $3.25 per share to stockholders
- Company is dissolving and ceasing all business operations
- Stock transfer books are closed with immediate effect
- Actual distribution amount could be less than estimated due to potential liabilities and expenses
- Shareholders can no longer transfer their shares except in circumstances
Insights
This dissolution announcement marks a critical juncture for Guardion Health Sciences, with significant implications for shareholders. The planned
- The final distribution amount remains uncertain and could be reduced by unforeseen liabilities or expenses
- The timing of distributions is not guaranteed
- Stock transfer restrictions are now in effect
- Trading liquidity will likely deteriorate significantly
The three-year wind-down period provides time for proper asset disposition and liability settlement, though this extended timeframe also introduces uncertainty regarding the ultimate value shareholders will receive. The suspension of SEC reporting obligations further reduces transparency during this critical phase.
The dissolution filing triggers several important legal mechanisms under Delaware law that significantly impact shareholder rights. Key legal considerations include:
- Automatic closure of stock transfer books, limiting share transfers except through specific legal channels like inheritance
- Implementation of a three-year statutory wind-down period
- Establishment of contingency reserves for potential future claims
- Protection mechanisms for creditor claims before shareholder distributions
The SEC reporting suspension, while reducing administrative burden, also means reduced regulatory oversight during the dissolution process. Shareholders should carefully document their holdings and monitor communications regarding distribution timing.
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the “Effective Date”). The filing of the certificate was made pursuant to the terms of the Company’s Plan of Liquidation and Dissolution (the “Plan”) approved by stockholders at the Company’s special meeting of stockholders held on May 31, 2024.
As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company’s common stock, par value
As previously announced, Guardion expects to pay to its stockholders of record as of the close of business on the Effective Date, a liquidating dividend in one or more distributions, in an amount that is anticipated to total approximately
After the Effective Date, Guardion will not engage in any business activities except to the extent necessary to preserve the value of any remaining assets, complete the wind down of its business affairs and distribute its assets in accordance with the Plan. Under the DGCL, Guardion will be continued for the term of three years following the Effective Date, or for such longer period as the Delaware Court of Chancery directs, for the purposes of prosecuting and defending suits by or against it and of enabling it to gradually settle and close the business, to dispose of and convey its property, to discharge its liabilities and to distribute to stockholders any remaining assets.
Guardion has been granted relief from the U.S. Securities and Exchange Commission (the “SEC”) to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Act”) and to file a Form 15 with the SEC in connection therewith. The Form 15 will serve as notice of suspension of the Company’s duty to file reports under Sections 13 and 15(d) of the Act.
Forward-Looking Statements
The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about the Company’s expectations, beliefs, plans or intentions regarding its business plans, financial condition, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.
These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the expected completion, timing and effects of the Company’s delisting, dissolution and implementation of the Plan, and the indefinite suspension of reporting obligations under the Act, the risks and uncertainties relating to the limited resources remaining available to the Company to wind up its business and operations, the tax and accounting consequences of the Company’s dissolution, the Company’s ability to satisfy its liabilities, fees, taxes and other obligations out of the limited resources remaining available to the Company, and the amount and timing of distributions that may be made to stockholders in connection with the Company’s dissolution and liquidation.
Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about Guardion Health Sciences, Inc., Contact:
investors@guardionhealth.com
Phone: 1-800 873-5141 Ext 208
FAQ
What is the expected liquidating dividend for Guardion Health Sciences (GHSI) shareholders?
When did Guardion Health Sciences (GHSI) file for dissolution?
Can Guardion Health Sciences (GHSI) shares still be transferred after October 30, 2024?